読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$2.00
−$0.01 · -0.50%
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
通常取引
$2.00
−$0.01 · -0.50%
日中の時刻はETです。市場データは遅延する場合があります。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
54
まちまち
リスク
62
高リスク
モメンタム
43
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 302.2万 USD | 176.1万 USD | 130.2万 USD | 6996.3万 USD | 257.3万 USD |
| 売上原価 | — | — | — | 139.7万 USD | 140.2万 USD |
| 粗利益 | 302.2万 USD | 176.1万 USD | 130.2万 USD | 6856.6万 USD | 117.1万 USD |
| 販売・一般管理 | 685.2万 USD | 609.6万 USD | 890.3万 USD | 5671万 USD | 8074.8万 USD |
| 営業費用 | 723.6万 USD | 660.5万 USD | 982.5万 USD | 5790.3万 USD | 8074.8万 USD |
| 受取利息 | 15万 USD | — | 30万 USD | — | — |
| 支払利息 | 8000 USD | — | 20万 USD | — | 3291.7万 USD |
| 減価償却費と償却費 | 119.3万 USD | 50.9万 USD | 92.2万 USD | 120万 USD | 73.6万 USD |
| 営業利益 | −421.4万 USD | −484.4万 USD | −852.3万 USD | 1066.3万 USD | −7957.7万 USD |
| 純利益 | −56.9万 USD | −218.1万 USD | −1027.8万 USD | 1.12億 USD | −1.72億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2022年5月9日 | 1:50 | — | — |
株式分割 | 2011年10月3日 | 1:100 | — | — |
株式分割 | 2009年7月27日 | 3:1 | — | — |
発効済み 2022年5月9日
1:50
発効済み 2011年10月3日
1:100
発効済み 2009年7月27日
3:1
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI53.26万0.00%2.3兆 USD0.03%$380.63+0.28%
Vanguard Extended Market ETFVXF23.84万0.00%954億 USD0.05%$233.54+0.17%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM3万0.03%1.17億 USD0.73%$15.89-0.06%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.01万0.00%61.68億 USD0.26%$68.05-0.09%
Dimensional - US Core Equity 2 ETFDFAC96520.00%881.95億 USD0.21%$45.175+0.14%
Dimensional - US Sustainability Core 1 ETFDFSU72240.00%23.79億 USD0.15%$47.965+0.18%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR61520.00%453.77億 USD0.17%$84.13+0.07%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
